Reviva Pharmaceuticals Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVPH research report →
About the company
Reviva Pharmaceuticals Holdings, Inc. , a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis.
- CEO
- Laxminarayan Bhat
- IPO
- 2020
- Employees
- 14
- HQ
- Cupertino, CA, US
Price Chart
- Market Cap
- $2.25M
- P/E
- -0.07
- P/S
- 0.00
- P/B
- 0.27
- EV/EBITDA
- 1.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -220.39%
- ROIC
- -95.82%
- Revenue
- $0 · 0.00%
- Net Income
- $-19,864,902 · 33.60%
- EPS
- $-5.48 · 69.56%
- Op Income
- $-20,200,031
- FCF YoY
- 26.68%
- 52W High
- $17.20
- 52W Low
- $0.26
- 50D MA
- $0.64
- 200D MA
- $5.44
- Beta
- 0.47
- Avg Volume
- 493.01K
Get TickerSpark's AI analysis on RVPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Prabhu Narayan | other | 40,925 |
| Mar 18, 26 | Bhat Laxminarayan | other | 109,150 |
| Mar 18, 26 | Bhat Laxminarayan | other | 40,925 |
| Dec 18, 25 | Funtleyder Leslie D. | other | 8,200 |
| Dec 18, 25 | Margolin Richard A | other | 8,200 |
| Dec 18, 25 | Patel Purav | other | 8,200 |
| Dec 18, 25 | SAXENA PARAG | other | 8,200 |
| Feb 13, 25 | Narayan Prabhu | other | 194,250 |
| Feb 13, 25 | Bhat Laxminarayan | other | 519,000 |
| Feb 13, 25 | Bhat Laxminarayan | other | 181,500 |
Our RVPH coverage
Recent articles, reports, and earnings notes.
No research on RVPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RVPH report →Similar companies
Peers in the same neighborhood.